Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10500734" target="_blank" >RIV/00216208:11110/25:10500734 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=No5HC0pgsd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=No5HC0pgsd</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jaip.2025.05.003" target="_blank" >10.1016/j.jaip.2025.05.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?

Popis výsledku v původním jazyce

Although numbers vary, most patients with severe asthma have eosinophilic asthma. Many of them have the allergic asthma endotype, particularly those with concomitant allergic rhinitis (AR). Allergen immunotherapy (AIT) is the only disease-modifying therapy offering long-term effectiveness for allergic respiratory disorders, including asthma, but it is contraindicated in patients with uncontrolled disease. Patients with severe asthma often have frequent exacerbations, making them poor candidates for AIT. However, after approximately 6 to 12 months on biologic therapy, many patients become exacerbation-free and obtain good symptom control and even improved lung function. Thus, in these patients, add-on AIT, subcutaneous or sublingual, is possible. Importantly, AIT could contribute to achieving clinical remission in severe asthma with biologic therapy, that even may be sustained after cessation of treatment. In a few landmark trials of AIT added to biologics (omalizumab, dupilumab, or tezepelumab), mechanisms were also studied, unveiling the additional benefit of these combinations in enhancing not only safety and tolerability, but possibly also efficacy. We present a summary of clinical trials combining immunotherapy with aeroallergens with biologic therapy in patients with respiratory allergy and discuss the cons and pros of AIT in patients with severe allergic asthma who received biological therapy, concluding that this combination could benefit many of these patients.

Název v anglickém jazyce

Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?

Popis výsledku anglicky

Although numbers vary, most patients with severe asthma have eosinophilic asthma. Many of them have the allergic asthma endotype, particularly those with concomitant allergic rhinitis (AR). Allergen immunotherapy (AIT) is the only disease-modifying therapy offering long-term effectiveness for allergic respiratory disorders, including asthma, but it is contraindicated in patients with uncontrolled disease. Patients with severe asthma often have frequent exacerbations, making them poor candidates for AIT. However, after approximately 6 to 12 months on biologic therapy, many patients become exacerbation-free and obtain good symptom control and even improved lung function. Thus, in these patients, add-on AIT, subcutaneous or sublingual, is possible. Importantly, AIT could contribute to achieving clinical remission in severe asthma with biologic therapy, that even may be sustained after cessation of treatment. In a few landmark trials of AIT added to biologics (omalizumab, dupilumab, or tezepelumab), mechanisms were also studied, unveiling the additional benefit of these combinations in enhancing not only safety and tolerability, but possibly also efficacy. We present a summary of clinical trials combining immunotherapy with aeroallergens with biologic therapy in patients with respiratory allergy and discuss the cons and pros of AIT in patients with severe allergic asthma who received biological therapy, concluding that this combination could benefit many of these patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Journal of Allergy and Clinical Immunology: In Practice

ISSN

2213-2198

e-ISSN

2213-2201

Svazek periodika

13

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

16

Strana od-do

1581-1596

Kód UT WoS článku

001533831000010

EID výsledku v databázi Scopus

2-s2.0-105007731706